Novo Nordisk and five other pharmaceutical companies have sued the US government – they argue the US discount system is poorly implemented in several US hospitals, driving uppatient costs.
The US Health Resources and Services Administration (HRSA) now responds by threatening a fine of USD 5,000 (DKK 31,741) per violation of the discount program in question, Danish business daily Børsen reports.
More from MedWatch
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.